
August 11, 2021

Listing Department
BOMBAY STOCK EXCHANGE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: CADILAHC

Re: **Outcome of Board Meeting**

Dear Sir/Madam,

The Board of Directors at their meeting held today i.e. August 11, 2021, based on the recommendations of Audit Committee, approved the Unaudited Financial Results for the quarter ended on June 30, 2021.

In this regard, please find enclosed the following:

1. the Unaudited Financial Results (standalone and consolidated) for the quarter ended on June 30, 2021, reviewed by the Audit Committee and taken on record by the Board of Directors pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the **Listing Regulations**").
2. the Limited Review Reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company certifying the limited review of the Unaudited Financial Results (standalone and consolidated) of the Company for the quarter ended on June 30, 2021 pursuant to regulation 33 of the Listing Regulations.
3. press release proposed to be published in the newspapers in the matter of Unaudited Financial Results for the quarter ended on June 30, 2021.
- The Trading Window under SEBI (Prohibition of Insider Trading Regulations), 2015 shall remain closed for trading till August 15, 2021 and shall reopen from August 16, 2021 for the Directors and Designated Persons.

- The Board Meeting commenced at 12:00 noon and concluded at 12:30 p.m.

Please receive the information and disclosures in order.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CADILA HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **CADILA HEALTHCARE LIMITED** ("the Company"), which includes a branch located at Philippines for the quarter ended June 30, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani
(Partner)
(Membership No. 36920)
(UDIN: 21036920AAAADK5904)

Place: MUMBAI
Date: August 11, 2021

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CADILA HEALTHCARE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **CADILA HEALTHCARE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its joint ventures for the quarter ended June 30, 2021 ("the Statement"), which includes a branch of the Group located at Philippines, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Deloitte Haskins & Sells LLP

4. The Statement includes the results of the entities listed in the Annexure to this report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of 24 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 23,977 Million for the quarter ended June 30, 2021, total net loss after tax of Rs. 320 Million for the quarter ended June 30, 2021 and total comprehensive loss of Rs. 315 Million for the quarter ended June 30, 2021, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

SA EN
RKB

Deloitte Haskins & Sells LLP

7. The consolidated unaudited financial results includes the interim financial information of 16 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs. 1,593 Million for the quarter ended June 30, 2021, net loss after tax of Rs. 4 Million for the quarter ended June 30, 2021 and total comprehensive loss of Rs. 4 Million for the quarter ended June 30, 2021, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs. 70 Million for the quarter ended June 30, 2021 and total comprehensive income of Rs. 70 Million for the quarter ended June 30, 2021, as considered in the Statement, in respect of 3 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani
Partner
(Membership No. 36920)
(UDIN: 21036920AAAADL7866)

Place: Mumbai
Date: August 11, 2021

SA *EN*

Deloitte Haskins & Sells LLP

ANNEXURE TO THE INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS:

Name of the Entities
Parent Cadila Healthcare Limited
Subsidiaries Sentynl Therapeutics Inc Zydus Animal Health & Investments Limited Zydus Healthcare (USA) LLC Zydus Healthcare Limited Zydus Healthcare Philippines Inc. Zydus International Private Limited Zydus Lanka (Private) Limited Zydus Noveltech Inc. Zydus Pharmaceuticals (USA) Inc. Zydus Wellness Limited Zydus Worldwide DMCC Dialforhealth Greencross Limited Dialforhealth Unity Limited Zydus Pharmaceuticals Limited Zydus Strategic Investments Limited Zydus VTEC Limited
Subsidiaries of Zydus Animal Health & Investments Limited Viona Pharmaceuticals Inc., USA Violio Healthcare Limited Biochem Pharmaceuticals Private Limited
Subsidiaries of Zydus Healthcare Limited German Remedies Pharma Private Limited M/s. Recon Pharmaceuticals and Investments
Subsidiaries of Zydus International Private Limited Zydus Pharmaceuticals Mexico SA De CV Zydus Pharmaceuticals Mexico Services Company SA De C.V.
Subsidiary of Zydus Noveltech Inc. Hercon Pharmaceuticals LLC
Subsidiaries of Zydus Pharmaceuticals (USA) Inc. Nesher Pharmaceuticals (USA) Inc ZyVet Animal Health Inc [USA]

SA EN
RKH

Deloitte Haskins & Sells LLP

Name of the Entities

Subsidiaries of Zydus Wellness Limited

Liva Investment Limited
Liva Nutritions Limited
Zydus Wellness Products Limited
Zydus Wellness International DMCC [Dubai]

Subsidiaries of Zydus Worldwide DMCC

Alidac Healthcare Myanmar Limited
Etna Biotech S.R.L.
Zydus Discovery DMCC
Zydus France SAS
Zydus Healthcare S.A. (Pty) Ltd.
Zydus Netherland B.V
Zydus Therapeutics Inc.

Subsidiaries of Zydus Healthcare S.A. (Pty) Ltd.

Script Management Services (Pty) Ltd.
Simayla Pharmaceuticals (Pty) Ltd.

Subsidiaries of Zydus Netherland B.V

Laboratorios Combix S.L.
Zydus Nikkho Farmaceutica Ltda.

Joint Ventures of Cadila Healthcare Limited

Bayer Zydus Pharma Private Limited
Zydus Hospira Oncology Private Limited
Zydus Takeda Healthcare Private Limited

SA EN

RKG



Cadila Healthcare Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0100 Website: www.zyduscadila.com
CIN : L24230GJ1995PLC025878

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30/06/2021

Sr. No.	Particulars	Rupees in Million			
		3 Months ended 30/06/2021	3 Months ended 31/03/2021	Corresponding 3 months ended 30/06/2020 in the previous year	Previous year ended 31/03/2021
		(Unaudited)	(Unaudited) (Refer Note-6)	(Unaudited)	(Audited)
1	Income				
a	Revenue from operations				
i	Sale of products	20,320	19,497	17,037	74,367
ii	Other operating revenues	914	587	922	3,433
iii	Total revenue from operations	21,234	20,084	17,959	77,800
b	Other income	297	(165)	200	893
c	Total income	21,531	19,919	18,159	78,693
2	Expenses				
a	Cost of materials consumed	7,015	5,920	5,205	23,464
b	Purchases of stock-in-trade	204	405	306	1,533
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(546)	(44)	(663)	(1,483)
d	Employee benefits expense	3,180	2,947	2,928	11,473
e	Finance costs	442	205	199	709
f	Depreciation and amortisation expense	1,167	1,150	1,109	4,511
g	Other expenses	5,205	4,918	4,291	19,726
h	Total expenses	16,667	15,501	13,375	59,933
3	Profit before exceptional items and tax (1-2)	4,864	4,418	4,784	18,760
4	Exceptional Item (Refer Note-2)	-	-	-	1,875
5	Profit before tax (3-4)	4,864	4,418	4,784	16,885
6	Tax expenses				
a	Current tax	850	555	841	3,033
b	Deferred tax (Refer Note-3)	15	(784)	(39)	(910)
c	Total tax (credit) expenses	865	(229)	802	2,123
7	Net Profit for the period/ year (5-6)	3,999	4,647	3,982	14,762
8	Other Comprehensive Income (OCI)				
	Items that will not be reclassified to profit or loss:				
i	Re-measurement gains/ (losses) on post employment defined benefit plans	(46)	62	(15)	(186)
ii	Net gain/ (loss) Fair Value through OCI Equity Securities	140	(3)	120	234
iii	Income tax effect on above items	8	(10)	3	33
iv	Other Comprehensive Income (net of tax)	102	49	108	81
9	Total Comprehensive Income (7+8)	4,101	4,696	4,090	14,843
10	Paid-up equity share capital (Face value Re. 1/-)	1,024	1,024	1,024	1,024
11	Reserves excluding Revaluation Reserve (i.e. Other Equity)				1,26,421
12	Earnings per share (not annualised for the quarter)				
a	Basic (Rs.)	3.91	4.54	3.89	14.42
b	Diluted (Rs.)	3.91	4.54	3.89	14.42

Notes :

- [1] The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 11, 2021.
- [2] Exceptional item for the previous year ended March 31, 2021 comprises of provision for impairment in the value of investment in the equity shares of Zydus International Private Limited, Ireland, a wholly owned subsidiary.
- [3] Deferred tax for the quarter and year ended March 31, 2021 includes INR 717 Million of benefit on account of recognition of deferred tax asset consequent to a merger of a wholly owned subsidiary with the Company.
- [4] The Company had issued unsecured Commercial Papers (CPs) during the previous year. The total CPs outstanding as at June 30, 2021 amounts to INR 6,250 Million. The CPs are repayable on October 22, 2021. The CPs are having credit rating of CRISIL A1+. There is no change in rating of CPs post their issuance.
- [5] As per the current assessment of the situation based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Company continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, goodwill, intangible assets, trade receivables, investments and other financial assets. The Company will closely monitor any material changes to the economic environment and their impact on its business in the times to come.
- [6] The figures of the quarter ended March 31, 2021 are balancing figures between audited figures in respect of the full financial year and year to date figures upto the third quarter of the said financial year.
- [7] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.
- [8] The Company has one segment of activity viz., "Pharmaceuticals".

By Order of the Board,
For Cadila Healthcare Limited,

Dr. Sharvil P. Patel
Managing Director

Ahmedabad, August 11, 2021

SA
RKH



Cadila Healthcare Limited

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0100 Website: www.zyduscadila.com
CIN : L24230GJ1995PLC025878

Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30/06/2021

Sr. No.	Particulars	Rupees in Million			
		3 Months ended 30/06/2021	3 Months ended 31/03/2021	Corresponding 3 months ended 30/06/2020 in the previous year	Previous year ended 31/03/2021
		(Unaudited)	Unaudited (Refer Note-7)	(Unaudited)	(Audited)
1	Income				
a	Revenue from operations				
i	Sale of products	39,174	36,022	34,241	1,42,190
ii	Other operating revenues	1,080	901	905	2,798
iii	Total revenue from operations	40,254	36,923	35,146	1,44,988
b	Other income	316	(305)	225	468
c	Total income	40,570	36,618	35,371	1,45,456
2	Expenses				
a	Cost of materials consumed	10,625	9,792	8,303	37,456
b	Purchases of stock-in-trade	4,490	3,601	3,251	12,893
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,367)	(849)	243	(1,562)
d	Employee benefits expense	6,542	6,101	6,114	24,394
e	Finance costs	273	232	677	1,632
f	Depreciation and amortisation expense	1,827	1,845	1,728	7,081
g	Other expenses	10,634	10,225	9,330	40,047
h	Total expenses	33,024	30,947	29,646	1,21,941
3	Profit before exceptional items, tax and share of profit of joint ventures (1-2)	7,546	5,671	5,725	23,515
4	Exceptional items (Refer Note-2)	-	731	-	2,051
5	Profit before tax and share of profit of joint ventures (3-4)	7,546	4,940	5,725	21,464
6	Tax expenses				
a	Current tax	1,281	1,149	1,065	4,530
b	Deferred tax (Refer Note-3)	134	(3,257)	117	(3,411)
c	Total tax (credit)/ expenses	1,415	(2,108)	1,182	1,119
7	Profit before share of profit of joint ventures (5-6)	6,131	7,048	4,543	20,345
8	Share of profit of joint ventures (net of tax)	70	38	167	474
9	Net profit before non-controlling interests (7+8)	6,201	7,086	4,710	20,819
10	Non-controlling interests	553	564	326	514
11	Net Profit for the period/ year from continuing operations (9-10)	5,648	6,522	4,384	20,305
12	Profit before tax from discontinued operations (Refer Note-4)	292	360	209	1,384
b	Tax expense of discontinued operations	(68)	(92)	(53)	(353)
c	Profit after tax from discontinued operations	224	268	156	1,031
13	Net profit for the period/ year (11+12)	5,872	6,790	4,540	21,336
14	Other Comprehensive Income (OCI)				
a	Items that will not be reclassified to profit or loss:				
i	Re-measurement gains/ (losses) on post employment defined benefit plans	(44)	70	(39)	(168)
ii	Net gain on Fair Value through OCI Equity Securities	142	-	122	245
iii	Income tax effect on above items	9	(10)	11	29
iv	Total	107	60	94	106
b	Items that will be reclassified to profit or loss:				
i	Exchange differences on translation of foreign operations	(509)	(43)	(322)	615
ii	Income tax effect on above items	-	-	-	-
iii	Total	(509)	(43)	(322)	615
c	Share of OCI of joint ventures (net of tax)	-	-	-	(2)
d	OCI of discontinued operations (net of tax)	-	21	-	12
e	Other Comprehensive Income (net of tax) before Non-Controlling Interests	(402)	38	(228)	731
f	Non-Controlling Interests	2	8	-	8
g	Other Comprehensive Income (net of tax)	(404)	30	(228)	723
15	Total Comprehensive Income (9+12+14)	6,023	7,392	4,638	22,581
16	Total Comprehensive Income attributable to:				
	Owners of the Company	5,468	6,820	4,312	22,059
	Non-Controlling Interests	555	572	326	522
17	Paid-up equity share capital (Face value Re. 1/-)	1,024	1,024	1,024	1,024
18	Reserves excluding Revaluation Reserve (i.e. Other Equity)				1,28,899
19	Earnings per share for continuing operations (not annualised for the quarter)				
A	Earnings per share for continuing operations (not annualised for the quarter)				
a	Basic (Rs.)	5.52	6.37	4.28	19.83
b	Diluted (Rs.)	5.52	6.37	4.28	19.83
B	Earnings per share for discontinued operations (not annualised for the quarter)				
a	Basic (Rs.)	0.22	0.26	0.15	1.01
b	Diluted (Rs.)	0.22	0.26	0.15	1.01
C	Earnings per share for continuing & discontinued operations (not annualised for the quarter)				
a	Basic (Rs.)	5.74	6.63	4.43	20.84
b	Diluted (Rs.)	5.74	6.63	4.43	20.84

Sa EN
RKG

Segment Information:					
Sr. No.	Particulars	Rupees in Million			
		3 Months ended 30/06/2021	3 Months ended 31/03/2021	Corresponding 3 months ended 30/06/2020 in the previous year	Previous year ended 31/03/2021
		(Unaudited)	Unaudited (Refer Note-7)	(Unaudited)	(Audited)
1	Segment revenue:				
a	Pharmaceuticals	34,392	30,939	29,830	1,26,579
b	Consumer Products	5,862	5,984	5,316	18,409
c	Total revenue from operations from continuing operations	40,254	36,923	35,146	1,44,988
2	Segment results:				
a	Pharmaceuticals	6,238	4,345	4,894	21,072
b	Consumer Products	1,308	1,326	831	2,443
c	Total profit before tax before exceptional items from continuing operations	7,546	5,671	5,725	23,515
3	Segment assets:				
a	Pharmaceuticals [*]	1,91,495	1,82,183	1,84,856	1,82,183
b	Consumer Products	57,108	56,664	56,312	56,664
c	Total assets	2,48,603	2,38,847	2,41,168	2,38,847
4	Segment liabilities:				
a	Pharmaceuticals [*]	87,678	83,673	98,652	83,673
b	Consumer Products	5,596	5,878	20,811	5,878
c	Total liabilities	93,274	89,551	1,19,463	89,551

[*] Includes amounts in respect of discontinued operations.

Notes :

[1] The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 11, 2021.

[2] Exceptional items comprise:

No.	Particulars	Rupees in Million			
		3 Months ended 30/06/2021	3 Months ended 31/03/2021	Corresponding 3 months ended 30/06/2020 in the previous year	Previous year ended 31/03/2021
		(Unaudited)	Unaudited (Refer Note-7)	(Unaudited)	(Audited)
a	Impairment charge on intangible asset relating to "Levorphanol", a product forming part of the US Specialty product segment	-	731	-	731
b	Premium on Non-Convertible Debentures upon their purchase by the Group	-	-	-	1,320
c	Total	-	731	-	2,051

[3] Deferred tax for the quarter and year ended March 31, 2021 includes the following:

- a INR 717 Million of benefit on account of recognition of deferred tax asset consequent to a merger of a wholly owned subsidiary with the Parent; and
b INR 2,180 Million of benefit on account of recognition of deferred tax asset on MAT credit of earlier years available to a wholly owned subsidiary (which was not recognised in past, but it had been recognised mainly on account of non-availability of depreciation on goodwill pursuant to an amendment to section 2(11) of the Income Tax Act in the Finance Act, 2021).

[4] On May 12, 2021, Zydus Animal Health and Investment Limited ["ZAHIL"], a wholly owned subsidiary of the Parent, entered into a Business Transfer Agreement ["BTA"] and other Ancillary Agreements [together "Definitive Agreements"] for sale of its Animal Healthcare Established Markets Undertaking ["AHESTM"], comprising animal healthcare business in India and certain other countries to Zenex Animal Health India Private Limited [formerly known as Nutrivit Animal Health India Private Limited] ["Purchaser"], by way of a slump sale, without values being assigned to the individual assets and liabilities, on a debt free and cash free basis, subject to certain closing date adjustments and other conditions specified in the BTA. The said transaction was approved by the shareholders of the Parent by way of a special resolution on June 11, 2021. The transaction of sale and disposal was completed on July 14, 2021. Consequently, AHESTM has been considered and disclosed as "Discontinued Operations" as per Ind AS 105 "Non-current Assets Held for Sale and Discontinued Operations". Accordingly, figures of all the prior periods have also been reclassified and disclosed separately under the head "Profit from the Discontinued Operations".

[5] As per the current assessment of the situation based on the internal and external information available up to the date of approval of these financial results by the Board of Directors, the Group continues to believe that the impact of Covid-19 on its business, assets, internal financial controls, profitability and liquidity, both present and future, would be limited and there is no indication of any material impact on the carrying amounts of inventories, goodwill, intangible assets, trade receivables, investments and other financial assets. The Group will closely monitor any material changes to the economic environment and their impact on its business in the times to come.

[6] The Parent had issued unsecured Commercial Papers [CPs] during the previous year. The total CPs outstanding as at June 30, 2021 amounts to INR 6,250 Million. The CPs are repayable on October 22, 2021. The CPs are having credit rating of CRISIL A1+. There is no change in rating of CPs post their issuance.

[7] The figures of the quarter ended March 31, 2021 are balancing figures between audited figures in respect of the full financial year and year to date figures upto the third quarter of the said financial year.

[8] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

[9] The detailed standalone results are available on the Company's website: www.zyduscadila.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com]. The summarised standalone financial results of the Company are as below:

Particulars	Rupees in Million			
	3 Months ended 30/06/2021	3 Months ended 31/03/2021	Corresponding 3 months ended 30/06/2020 in the previous year	Previous year ended 31/03/2021
	(Unaudited)	Unaudited (Refer Note-7)	(Unaudited)	(Audited)
Revenue from operations	21,234	20,084	17,959	77,800
Profit before Tax	4,864	4,418	4,784	16,885
Profit after Tax	3,999	4,647	3,982	14,762

By Order of the Board,
For Cadila Healthcare Limited,


Dr. Sharvil P. Patel
Managing Director

Ahmedabad, August 11, 2021

SA EN
RKB

Zydus Cadila's Q1 Net Profit up by 29%

Ahmedabad, August 11, 2021

For the first quarter ended June 30, 2021, Zydus Cadila reported net profit of Rs. 587 crores, up by 29% on a y-o-y basis. Total income from operations for the quarter was Rs. 4025 crores, up 15% on a y-o-y basis. Earnings before Interest, Depreciation and Tax (EBIDTA) for the quarter was Rs. 933 crores up by 18% y-o-y. The EBIDTA margin for the quarter was 23.2%, an improvement of 140 basis points q-o-q.

The company's India business which comprises human formulations and consumer wellness business which contributed to 50% of consolidated revenues during the quarter, witnessed a very strong growth of 43% on a y-o-y basis, posting sales of Rs.1943 crores during the quarter. The company's business in the US posted sales of Rs. 1451 crores. The company's rest of the world business grew by 17% during the quarter on a y-o-y basis and posted sales of Rs. 277 crores.

The company's lead molecule Saroglitazar Mg, received 'Orphan Drug Designation' from the European Medicines Agency (EMA) for the treatment of patients with Primary Biliary Cholangitis (PBC). It provides a 10-year period of market exclusivity if the treatment is eventually approved. Earlier the USFDA had granted 'Orphan Drug Designation' and 'Fast Track Designation' to Saroglitazar Mg for PBC.

During the quarter, the company launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer under the brand name 'Ujvira'. The drug has significantly reduced the treatment cost by almost 80% for patients.

Continuing with its fight against the pandemic, the company has also undertaken research in monoclonal antibodies cocktail to neutralise COVID infection. The company initiated the clinical trials of its monoclonal antibodies cocktail that can neutralise COVID-19 infection. ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19. Zydus is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID 19.

Continuing with its efforts to provide easily accessible therapy to fight Black Fungus or Mucormycosis in India, Zydus and TLC a specialty pharmaceutical company in Taiwan signed a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India.

The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoV-D, World's first Plasmid DNA Vaccine for human use after conducting the largest vaccine trial so far in India for COVID-19.

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878